Products
Tegoprubart Biosimilar Monoclonal Antibody (CD40L) for Research
Cat No.: GMP-Bios-INN-1411
Anti-CD40LG/CD154 therapeutic antibody (Pre-made Tegoprubart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tegoprubart (development code AT-1501) is a chimeric monoclonal antibody targeting CD40 ligand (CD40LG). It is developed by ALS Therapy Development Institute and Eledon Pharmaceuticals for Allotransplant rejection, Amyotrophic lateral sclerosis, IgA nephropathy et al. in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1411-1mg | 1mg | 3090 |
| GMP-Bios-INN-1411-10mg | 10mg | |
| GMP-Bios-INN-1411-100mg | 100mg | |
| GMP-Bios-INN-1411-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tegoprubart biosimilar, Whole mAb, Anti-CD40LG/CD154 Antibody: Anti-CD40LG/CD154/CD40 ligand/CD40-L therapeutic antibody |
| INN Name | Tegoprubart |
| Target | CD40LG/CD154 |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 1i9r:HL:KM:XY/6w4w:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | ALS Therapy Development Institute;Eledon Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Allotransplant rejection;Amyotrophic lateral sclerosis;IgA nephropathy;Renal transplant rejection;Autoimmune disorders |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
